DR. JEFFREY ADAM ENGELMAN, MD PHD
Osteopathic Medicine at Fruit St, Boston, MA
License number
Massachusetts 218378
Category
Osteopathic Medicine
Type
Internal Medicine
Address
Address
55 Fruit St, Boston, MA 02114
Phone
(617) 724-4000
Personal information
See more information about JEFFREY ADAM ENGELMAN at radaris.comName
Address
Phone
199 Massachusetts Ave APT 506, Boston, MA 02115
92 Coolidge St, Brookline, MA 02446
Professional information
Dr. Jeffrey A Engelman, Boston MA - MD (Doctor of Medicine)
Specialties:
Oncology, Medical Oncology
Address:
Department of Medicine
55 Fruit St, Boston 02114
(617) 724-4000 (Phone)
55 Fruit St, Boston 02114
(617) 724-4000 (Phone)
Certifications:
Internal Medicine, 2004, Medical Oncology, 2005
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
Department of Medicine
55 Fruit St, Boston 02114
Massachusetts General Hospital
55 Fruit St, Boston 02114
55 Fruit St, Boston 02114
Massachusetts General Hospital
55 Fruit St, Boston 02114
Education:
Medical School
Albert Einstein College of Medicine of Yeshiva University
Graduated: 1997
Brigham and Women's Hospital
Dana Farber Cancer Institute
Albert Einstein College of Medicine of Yeshiva University
Graduated: 1997
Brigham and Women's Hospital
Dana Farber Cancer Institute
Methods For Treating Cancer Resistant To Erbb Therapeutics
US Patent:
2012022, Sep 6, 2012
Filed:
Apr 11, 2008
Appl. No.:
12/450826
Inventors:
Pasi A. Janne - Newton MA, US
Jeffrey Engelman - Chestnut Hill MA, US
Lewis C. Cantley - Cambridge MA, US
Jeffrey Engelman - Chestnut Hill MA, US
Lewis C. Cantley - Cambridge MA, US
International Classification:
A61K 31/5377, C12Q 1/68, A61K 31/517, A61P 35/00, A61K 31/506
US Classification:
5142345, 51425218, 5142664, 435 611
Abstract:
Provided herein are methods for treating cancer that is resistant to treatment with an anti-ErbB therapeutic agent and which is associated with an activating MET gene mutation or a MET gene amplification. The methods involve administering to a subject a combination of an anti-ErbB therapeutic and an anti-MET therapeutic. Also provided are methods for reducing ErbB mediated signaling or PI3 kinase mediated signaling in a cancer cell.